Singapore accelerates multi-omics innovation in pharmaceutical sciences<\/h3>\n\n\n\nMarch 21, 2026 | Saturday | News<\/p>\n<\/p><\/div>\n<\/p><\/div>\n<\/p><\/div>\n
\nBenefiting the broader healthcare ecosystem through enhanced drug discovery capabilities<\/h5>\n<\/p><\/div>\n\n\t\t\t\t\t\t\t\t![\"image](\"https:\/\/www.biospectrumasia.com\/uploads\/articles\/screenshot_21_3_2026_171958_www_bing_com-27383.jpeg\")
<\/p>\nimage credit- freepik<\/p>\n<\/p><\/div>\n
MGI Tech Singapore, and the Department of Pharmacy and Pharmaceutical Sciences in the National University of Singapore’s Faculty of Science (NUS PPS) have announced a collaboration on a multi-omics laboratory.<\/p>\n
As part of MGI’s global DCS Lab initiative, this joint effort integrates MGI’s cutting-edge genomic sequencing and multi-omics technologies into pharmaceutical education, research, and drug discovery.<\/p>\n
Under this collaboration, MGI will support NUS PPS in establishing a high-performance multi-omics environment. The lab features an integrated instrument portfolio designed to provide deep insights across DNA genomics, cell omics, and spatial omics.<\/p>\n
This suite of technology offers a streamlined and efficient workflow, enabling NUS PPS researchers to execute complex assignments across various omics layers for applications in precision medicine, drug discovery, and pharmaceutical sciences.<\/p>\n
The lab is positioned to become a critical incubator for pharmaceutical innovation, ultimately benefiting the broader healthcare ecosystem through enhanced drug discovery capabilities.<\/p>\n
Launched in 2023, MGI’s DCS Lab Initiative represents the company’s first global programme targeting international laboratories with a focus on frontier science. The initiative is named after MGI’s three core technologies: DNA genomics, cell omics, and spatial omics. To date, MGI has supported the establishment of more than 30 DCS labs worldwide, empowering scientists to push the boundaries of life science.<\/p>\n<\/p><\/div>\n
March 21, 2026 | Saturday | News<\/p>\n<\/p><\/div>\n<\/p><\/div>\n<\/p><\/div>\n
Benefiting the broader healthcare ecosystem through enhanced drug discovery capabilities<\/h5>\n<\/p><\/div>\n\n\t\t\t\t\t\t\t\t<\/p>\nimage credit- freepik<\/p>\n<\/p><\/div>\n
MGI Tech Singapore, and the Department of Pharmacy and Pharmaceutical Sciences in the National University of Singapore’s Faculty of Science (NUS PPS) have announced a collaboration on a multi-omics laboratory.<\/p>\n
As part of MGI’s global DCS Lab initiative, this joint effort integrates MGI’s cutting-edge genomic sequencing and multi-omics technologies into pharmaceutical education, research, and drug discovery.<\/p>\n
Under this collaboration, MGI will support NUS PPS in establishing a high-performance multi-omics environment. The lab features an integrated instrument portfolio designed to provide deep insights across DNA genomics, cell omics, and spatial omics.<\/p>\n
This suite of technology offers a streamlined and efficient workflow, enabling NUS PPS researchers to execute complex assignments across various omics layers for applications in precision medicine, drug discovery, and pharmaceutical sciences.<\/p>\n
The lab is positioned to become a critical incubator for pharmaceutical innovation, ultimately benefiting the broader healthcare ecosystem through enhanced drug discovery capabilities.<\/p>\n
Launched in 2023, MGI’s DCS Lab Initiative represents the company’s first global programme targeting international laboratories with a focus on frontier science. The initiative is named after MGI’s three core technologies: DNA genomics, cell omics, and spatial omics. To date, MGI has supported the establishment of more than 30 DCS labs worldwide, empowering scientists to push the boundaries of life science.<\/p>\n<\/p><\/div>\n
<\/p>\nimage credit- freepik<\/p>\n<\/p><\/div>\n
MGI Tech Singapore, and the Department of Pharmacy and Pharmaceutical Sciences in the National University of Singapore’s Faculty of Science (NUS PPS) have announced a collaboration on a multi-omics laboratory.<\/p>\n
As part of MGI’s global DCS Lab initiative, this joint effort integrates MGI’s cutting-edge genomic sequencing and multi-omics technologies into pharmaceutical education, research, and drug discovery.<\/p>\n
Under this collaboration, MGI will support NUS PPS in establishing a high-performance multi-omics environment. The lab features an integrated instrument portfolio designed to provide deep insights across DNA genomics, cell omics, and spatial omics.<\/p>\n
This suite of technology offers a streamlined and efficient workflow, enabling NUS PPS researchers to execute complex assignments across various omics layers for applications in precision medicine, drug discovery, and pharmaceutical sciences.<\/p>\n
The lab is positioned to become a critical incubator for pharmaceutical innovation, ultimately benefiting the broader healthcare ecosystem through enhanced drug discovery capabilities.<\/p>\n
Launched in 2023, MGI’s DCS Lab Initiative represents the company’s first global programme targeting international laboratories with a focus on frontier science. The initiative is named after MGI’s three core technologies: DNA genomics, cell omics, and spatial omics. To date, MGI has supported the establishment of more than 30 DCS labs worldwide, empowering scientists to push the boundaries of life science.<\/p>\n<\/p><\/div>\n